This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CNTAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Smucker (SJM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Smucker (SJM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SJMNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Dave & Buster's (PLAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dave & Buster's (PLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLAYPositive Net Change CBRLNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does Arcosa (ACA) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Arcosa (ACA) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ACAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IMTXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ARCTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 44.7% Upside in Contango ORE, Inc. (CTGO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Contango ORE, Inc. (CTGO) points to a 44.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CTGONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AARDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Skillsoft Corp. (SKIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Skillsoft (SKIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKILPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe Ooma (OOMA) Could Rally 34.07%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 34.1% upside potential for Ooma (OOMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OOMAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ORICPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MNMDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CADLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 93.61% Upside in Vertical Aerospace (EVTL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 93.6% in Vertical Aerospace (EVTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EVTLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 27.7% Upside in European Wax Center (EWCZ): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in European Wax Center (EWCZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EWCZPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CPRXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 90% Upside in Backblaze (BLZE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90% in Backblaze (BLZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BLZEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 106.9% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KMDAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
IMCRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Semtech (SMTC) Have the Potential to Rally 50.9% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 50.9% upside potential for Semtech (SMTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SMTCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 59.92% Upside in Spire (SPIR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 59.9% in Spire (SPIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SPIRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Xperi (XPER) Could Surge 134.27%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Xperi (XPER) points to a 134.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
XPERPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Pan American Silver (PAAS) Have the Potential to Rally 29.05% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Pan American Silver (PAAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PAASPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Pagaya Technologies Ltd. (PGY) Could Surge 28.6%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Pagaya Technologies Ltd. (PGY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PGYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 25.17% Upside in Nexxen International Ltd. Sponsored ADR (NEXN): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Nexxen International Ltd. Sponsored ADR (NEXN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NEXNPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate